Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 22

Sort by

Sort Order Select

Journal Articles

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

Bruce D. Cheson, Geoffrey P. Shouse, Sarit Assouline, Katharine L. Lewis, Eliza A Hawkes, Talha Munir, Andrew S. Davies, Petra Langerbeins, Constantine S. Tam, Gareth P. Gregory, Michael Y. Choi, William Sun, Siminder K. Atwal, Wan-Jen Hong, Clémentine Sarkozy

Blood (2023) 142 (Supplement 1): 6324.

https://doi.org/10.1182/blood-2023-182434

Published: 2023

Journal Articles

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

Manish R. Patel, Varun Monga, Shekeab Jauhari, Don Stevens, Lucia Masarova, Meredith McKean, David Mauro, John Viscusi, Peggy Scherle, Neha Bhagwat, Andrew Moore, William Sun, Rachel Chiaverelli, Eric Mintah, Rajneesh Nath, Eytan M. Stein, Neil Palmisiano, Grerk Sutamtewagul, Srdan Verstovsek

Blood (2021) 138 (Supplement 1): 2609.

https://doi.org/10.1182/blood-2021-150938

Published: 2021

Journal Articles

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Srdan Verstovsek, MD PhD, Vikas Gupta, MD FRCP, FRCPath, Jason R. Gotlib, MD, Ruben A. Mesa, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Touchuan Dong, Ahmad Naim, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2016) 128 (22): 3110.

https://doi.org/10.1182/blood.V128.22.3110.3110

Published: 2016

Journal Articles

Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

Vikas Gupta, MD FRCP, FRCPath, Srdan Verstovsek, MD PhD, Ronald Paquette, MD, Jason R. Gotlib, MD, Alessandro M. Vannucchi, MD, Jean-Jacques Kiladjian, MD PhD, Francisco Cervantes, MD PhD, William Sun, PhD, Jessy Gao, MA, Peter Langmuir, MD, Prashanth Gopalakrishna, MBBS, MRCS, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2016) 128 (22): 3118.

https://doi.org/10.1182/blood.V128.22.3118.3118

Published: 2016

Journal Articles

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Ahmad Naim, MD, Smitha Svaraman, PhD, Jessy Gao, MA, Jason R. Gotlib, MD, Vikas Gupta, MD FRCP, FRCPath, Kim-Hien Dao, DO, PhD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Srdan Verstovsek, MD PhD

Blood (2016) 128 (22): 1949.

https://doi.org/10.1182/blood.V128.22.1949.1949

Published: 2016

Journal Articles

The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial

Carole B. Miller, MD, Jean-Jacques Kiladjian, MD PhD, Martin Griesshammer, MD, Ahmad B. Naim, MD, William Sun, PhD, Brian Gadbaw, MD, Srdan Verstovsek, MD PhD, Alessandro M. Vannucchi

Blood (2015) 126 (23): 4070.

https://doi.org/10.1182/blood.V126.23.4070.4070

Published: 2015

Journal Articles

Practical Measures of Clinical Benefit with Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

Carole B Miller, MD, Rami S Komrokji, MD, Ruben Mesa, MD, William Sun, PhD, Michael Montgomery, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3202.

https://doi.org/10.1182/blood.V124.21.3202.3202

Published: 2014

Journal Articles

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

Hans Michael Kvasnicka, MD PhD, Juergen Thiele, MD PhD, Carlos E. Bueso-Ramos, MD PhD, William Sun, PhD, Jorge E. Cortes, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD PhD

Blood (2014) 124 (21): 3182.

https://doi.org/10.1182/blood.V124.21.3182.3182

Published: 2014

Journal Articles

Optimizing Dose Titration Of Ruxolitinib: The COMFORT-I Experience

Ruben A. Mesa, MD, Rami S. Komrokji, MD, William Sun, PhD, Victor A. Sandor, MD, CM, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4062.

https://doi.org/10.1182/blood.V122.21.4062.4062

Published: 2013

Journal Articles

Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy

Hans Michael Kvasnicka, MD, PhD, Jürgen Thiele, MD, PhD, Carlos E. Bueso-Ramos, MD, PhD, William Sun, PhD, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Srdan Verstovsek, MD, PhD

Blood (2013) 122 (21): 4055.

https://doi.org/10.1182/blood.V122.21.4055.4055

Published: 2013

Journal Articles

Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I

Blood (2013) 122 (21): 396.

https://doi.org/10.1182/blood.V122.21.396.396

Published: 2013

Journal Articles

Clinical Benefits of Ruxolitinib Therapy in Myelofibrosis Patients with Varying Degrees of Splenomegaly and Symptoms

Ruben A. Mesa, Jason Gotlib, Hagop M. Kantarjian, MD, William Sun, PhD, Srdan Verstovsek, MD, PhD

Blood (2012) 120 (21): 1727.

https://doi.org/10.1182/blood.V120.21.1727.1727

Published: 2012

Journal Articles

Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I

Ruben A. Mesa, Srdan Verstovsek, MD, PhD, Vikas Gupta, MD, FRCP, FRCPath, John Mascarenhas, MD, Ehab Atallah, MD, William Sun, PhD, Victor A. Sandor, MD, CM, Jason Gotlib

Blood (2012) 120 (21): 1733.

https://doi.org/10.1182/blood.V120.21.1733.1733

Published: 2012

Journal Articles

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

Blood (2012) 120 (21): 800.

https://doi.org/10.1182/blood.V120.21.800.800

Published: 2012

Journal Articles

Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,

Ruben A. Mesa, MD, Jason Gotlib, MD, MS, Vikas Gupta, MD, FRCP, FRCPath, John F. DiPersio, MD, PhD, John Catalano, MD, Michael W. Deininger, Alan Shields, PhD, Carole B. Miller, MD, Richard T. Silver, MD, Moshe Talpaz, MD, Elliott F. Winton, MD, Jimmie H. Harvey, Jr., MD, Thomas Hare, PhD, Sue Erickson-Viitanen, PhD, William Sun, PhD, Victor A. Sandor, MD, CM, Richard S. Levy, MD, Hagop M. Kantarjian, Srdan Verstovsek, MD, PhD

Blood (2011) 118 (21): 3842.

https://doi.org/10.1182/blood.V118.21.3842.3842

Published: 2011

Journal Articles

Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I)

Blood (2011) 118 (21): 5146.

https://doi.org/10.1182/blood.V118.21.5146.5146

Published: 2011

Journal Articles

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I

Blood (2011) 118 (21): 278.

https://doi.org/10.1182/blood.V118.21.278.278

Published: 2011

Journal Articles

Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies

Ruben A. Mesa, MD, Srdan Verstovsek, MD, PhD, Francisco Cervantes, MD, PhD, Roger J. Waltzman, MD, Estella T. Mendelson, BSRN, MBA, Nicolas Martin, MS, William Sun, PhD, Victor A. Sandor, MD, CM, Richard S. Levy, MD, Claire N. Harrison, DM, FRCP, FRCPath

Blood (2011) 118 (21): 1753.

https://doi.org/10.1182/blood.V118.21.1753.1753

Published: 2011

Journal Articles

Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain

Eric S. Mullins, Keith W. Kombrinck, Kathryn E. Talmage, Maureen A. Shaw, David P. Witte, Joni M. Ullman, Sandra J. Degen, William Sun, Matthew J. Flick, Jay L. Degen

Blood (2009) 113 (3): 696–704.

https://doi.org/10.1182/blood-2008-07-169003

Published: 2009

Includes: Supplemental data

Journal Articles

Genetic Elimination of Prothrombin in Adult Mice Results in Fatal Spontaneous Hemorrhage in the Heart and Central Nervous System

Eric S. Mullins, MD, Keith W. Kombrinck, Kathryn E. Talmage, Maureen A. Shaw, David P. Witte, Joni M. Ullman, Sandra J. Degen, William Sun, Matthew Flick, PhD, Jay Degen

Blood (2008) 112 (11): 395.

https://doi.org/10.1182/blood.V112.11.395.395

Published: 2008

NARROW

A Phase 1 Study Evaluating PRT2527, a Potent and Highly Selective CDK9 Inhibitor, As Monotherapy and in Combination with Zanubrutinib in Patients with Select Relapsed/Refractory B-Cell Malignancies

A Phase 1 Dose Escalation Study of Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor PRT543 in Patients with Myeloid Malignancies

A Pooled Overall Survival (OS) Analysis of 5-Year Data from the COMFORT-I and COMFORT-II Trials of Ruxolitinib for the Treatment of Myelofibrosis (MF)

Clinical Outcomes with Ruxolitinib (RUX) in Patients with Myelofibrosis (MF) Stratified By Transfusion Status: A Pooled Analysis of the COMFORT-I and -II Trials

Effects of Long-Term Ruxolitinib (RUX) on Bone Marrow (BM) Morphology in Patients with Myelofibrosis (MF) Enrolled in the COMFORT-I Study

The Effect of Ruxolitinib on White Blood Cell Counts in Patients with Polycythemia Vera: Results from the RESPONSE Trial

Practical Measures of Clinical Benefit with Ruxolitinib Therapy: An Exploratory Analysis of COMFORT-I

Ruxolitinib-Induced Modulation of Bone Marrow Microenvironment in Patients with Myelofibrosis Is Associated with Inflammatory Cytokine Levels

Optimizing Dose Titration Of Ruxolitinib: The COMFORT-I Experience

Effects Of Five-Years Of Ruxolitinib Therapy On Bone Marrow Morphology In Patients With Myelofibrosis and Comparison With Best Available Therapy

Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I

Clinical Benefits of Ruxolitinib Therapy in Myelofibrosis Patients with Varying Degrees of Splenomegaly and Symptoms

Improvement in Weight and Total Cholesterol and Their Association with Survival in Ruxolitinib-Treated Patients with Myelofibrosis From COMFORT-I

Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I

Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF,

Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I)

Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I

Comparison of the Efficacy of Placebo and Best Available Therapy for the Treatment of Myelofibrosis in the COMFORT Studies

Genetic elimination of prothrombin in adult mice is not compatible with survival and results in spontaneous hemorrhagic events in both heart and brain

Genetic Elimination of Prothrombin in Adult Mice Results in Fatal Spontaneous Hemorrhage in the Heart and Central Nervous System

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only